<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 7, 2026 at 2:39 am by All in One SEO v5.0.5 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Sat, 07 Nov 2026 02:38:26 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://www.nature.com/articles/d41573-026-00178-3]]></guid>
			<link><![CDATA[https://www.nature.com/articles/d41573-026-00178-3]]></link>
			<title>Regulatory lessons from FDA review of approved AAV gene therapies</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 02:38:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/d41573-026-00173-8]]></guid>
			<link><![CDATA[https://www.nature.com/articles/d41573-026-00173-8]]></link>
			<title>Decision quality in biopharma portfolio renewal</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 02:38:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/sareptas-new-ceo-confident-in-clinical-execution-as-dmd-competitors-close-in]]></guid>
			<link><![CDATA[https://www.biospace.com/business/sareptas-new-ceo-confident-in-clinical-execution-as-dmd-competitors-close-in]]></link>
			<title>Sarepta’s new CEO confident in clinical execution as DMD competitors close in</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:26:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-delivery/forges-piteri-molina-on-ai-ohio-and-whats-next-for-gene-therapy-manufacturing]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-delivery/forges-piteri-molina-on-ai-ohio-and-whats-next-for-gene-therapy-manufacturing]]></link>
			<title>Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:26:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/verdicts-for-summit-akeso-capricor-vertex-mark-fdas-stacked-november]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/verdicts-for-summit-akeso-capricor-vertex-mark-fdas-stacked-november]]></link>
			<title>Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:15:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/verdicts-for-summit-akeso-capricor-vertex-mark-fdas-stacked-november]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/verdicts-for-summit-akeso-capricor-vertex-mark-fdas-stacked-november]]></link>
			<title>Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:15:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/agios-axes-100-plus-r-d-roles-while-awaiting-fda-decision]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/agios-axes-100-plus-r-d-roles-while-awaiting-fda-decision]]></link>
			<title>Agios axes 100-plus R&amp;D roles while awaiting FDA decision</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:15:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/moderna-enjoys-stable-vaccine-sales-thanks-to-global-covid-uptake]]></guid>
			<link><![CDATA[https://www.biospace.com/business/moderna-enjoys-stable-vaccine-sales-thanks-to-global-covid-uptake]]></link>
			<title>Moderna enjoys stable vaccine sales thanks to global COVID uptake</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:15:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/agios-axes-100-plus-r-d-roles-while-awaiting-fda-decision]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/agios-axes-100-plus-r-d-roles-while-awaiting-fda-decision]]></link>
			<title>Agios axes 100-plus R&amp;D roles while awaiting FDA decision</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:15:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/moderna-enjoys-stable-vaccine-sales-thanks-to-global-covid-uptake]]></guid>
			<link><![CDATA[https://www.biospace.com/business/moderna-enjoys-stable-vaccine-sales-thanks-to-global-covid-uptake]]></link>
			<title>Moderna enjoys stable vaccine sales thanks to global COVID uptake</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:15:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/moderna-enjoys-stable-vaccine-sales-thanks-to-global-covid-uptake]]></guid>
			<link><![CDATA[https://www.biospace.com/business/moderna-enjoys-stable-vaccine-sales-thanks-to-global-covid-uptake]]></link>
			<title>Moderna enjoys stable vaccine sales thanks to global COVID uptake</title>
			<pubDate><![CDATA[Sat, 07 Nov 2026 01:15:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/alethio-therapeutics-myeloproliferative-neoplasms-series-a/873775/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/alethio-therapeutics-myeloproliferative-neoplasms-series-a/873775/]]></link>
			<title>Alethio raises $90M to target rare blood cancers</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 20:36:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/t-therapeutics-series-b-tces-bispecifics-cancer-autoimmune/873786/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/t-therapeutics-series-b-tces-bispecifics-cancer-autoimmune/873786/]]></link>
			<title>T-Therapeutics reloads with a $133M megaround for bispecifics</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 20:36:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/biotech-charts-drug-launches-sales-wegovy-rezdiffra-auvelity/873549/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/biotech-charts-drug-launches-sales-wegovy-rezdiffra-auvelity/873549/]]></link>
			<title>This week in charts: 3 drug launches Wall Street is watching</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 20:36:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/lilly-hims-alnylam-boehringer-ultragenyx-sevasemten-ani-egetis/873843/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/lilly-hims-alnylam-boehringer-ultragenyx-sevasemten-ani-egetis/873843/]]></link>
			<title>Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 20:36:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/zolgensma-tumor-report-novartis-sma-spinal-muscular-atrophy/873990/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/zolgensma-tumor-report-novartis-sma-spinal-muscular-atrophy/873990/]]></link>
			<title>Novartis reveals cancer cases possibly linked to gene therapy Zolgensma</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 20:36:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma]]></guid>
			<link><![CDATA[http://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma]]></link>
			<title>FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 16:56:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/about-fda/office-health-advancement/office-health-advancement-oha-guidance-documents]]></guid>
			<link><![CDATA[http://www.fda.gov/about-fda/office-health-advancement/office-health-advancement-oha-guidance-documents]]></link>
			<title>Office of Health Advancement (OHA) Guidance Documents</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 16:56:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and]]></link>
			<title>FDA grants accelerated approval to amivantamab and hyaluronidase-lpuj for recurrent or metastatic head and neck squamous cell carcinoma</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 16:56:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></guid>
			<link><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></link>
			<title>Voyager, C4 cut workforces</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 15:46:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></link>
			<title>Drugs@FDA Data Files</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 14:50:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661475/nisa-leung-s-aulis-capital-closes-200m-debut-fund-venture-report?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661475/nisa-leung-s-aulis-capital-closes-200m-debut-fund-venture-report?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Nisa Leung’s Aulis Capital closes $200M debut fund: Venture Report</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 13:44:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661469/alethio-a-mutation-agnostic-approach-to-essential-thrombocythemia?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661469/alethio-a-mutation-agnostic-approach-to-essential-thrombocythemia?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Alethio: A mutation-agnostic approach to essential thrombocythemia</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 13:44:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661465/with-600m-fund-formation-bio-puts-a-financing-twist-on-hub-and-spoke-model?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661465/with-600m-fund-formation-bio-puts-a-financing-twist-on-hub-and-spoke-model?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>With $600M fund, Formation Bio puts a financing twist on hub-and-spoke model</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 13:44:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://phys.org/news/2026-11-citizen-science-exotic.html]]></guid>
			<link><![CDATA[https://phys.org/news/2026-11-citizen-science-exotic.html]]></link>
			<title>Citizen science program helps find exotic ticks</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 12:27:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/dren-bio-350m-dibotatug-clinical-development/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/dren-bio-350m-dibotatug-clinical-development/]]></link>
			<title>Dren Bio raises $350m for dibotatug clinical development</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/glenmark-opens-allentown-distribution-hub-us/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/glenmark-opens-allentown-distribution-hub-us/]]></link>
			<title>Glenmark opens Allentown distribution hub in US</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/pelthos-castle-creek-merger/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/pelthos-castle-creek-merger/]]></link>
			<title>Pelthos and Castle Creek plan merger to target skin diseases</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/inovios-voceryq-fda-approval/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/inovios-voceryq-fda-approval/]]></link>
			<title>Inovio’s Voceryq receives FDA accelerated approval for RRP</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/bavarian-nordic-uk-vaccine-supply-deal/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/bavarian-nordic-uk-vaccine-supply-deal/]]></link>
			<title>Bavarian Nordic secures four-year UK vaccine supply deal</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/lonza-us-manufacturing-sites/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/lonza-us-manufacturing-sites/]]></link>
			<title>Lonza to acquire five US manufacturing sites from Merck KGaA</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/fda-uniqures-bla-huntingtons-therapy/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/fda-uniqures-bla-huntingtons-therapy/]]></link>
			<title>FDA to review uniQure’s BLA for Huntington’s gene therapy</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.pharmaceutical-business-review.com/news/gebro-spektus-agreement-actraflex/]]></guid>
			<link><![CDATA[https://www.pharmaceutical-business-review.com/news/gebro-spektus-agreement-actraflex/]]></link>
			<title>GEBRO and Spektus sign collaboration for ActraFlex</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 09:48:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/05/india-new-manufacturing-rules-china-clinical-trials/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/05/india-new-manufacturing-rules-china-clinical-trials/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:47:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/omics/revealing-the-chemistry-around-us-through-mass-spectrometry/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/omics/revealing-the-chemistry-around-us-through-mass-spectrometry/]]></link>
			<title>Revealing the Chemistry Around Us Through Mass Spectrometry</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:39:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/insights/what-biotech-licensing-really-buys/]]></guid>
			<link><![CDATA[https://www.genengnews.com/insights/what-biotech-licensing-really-buys/]]></link>
			<title>What Biotech Licensing Really Buys</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:39:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/insights/beyond-conventional-crispr/]]></guid>
			<link><![CDATA[https://www.genengnews.com/insights/beyond-conventional-crispr/]]></link>
			<title>Beyond Conventional CRISPR</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:37:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/translational-medicine/oral-sleep-apnea-therapy-poised-to-expand-treatment-options/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/translational-medicine/oral-sleep-apnea-therapy-poised-to-expand-treatment-options/]]></link>
			<title>Oral Sleep Apnea Therapy Poised to Expand Treatment Options</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:37:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/bioprocessing/beyond-the-payload/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/bioprocessing/beyond-the-payload/]]></link>
			<title>Beyond the Payload</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:37:01 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/translational-medicine/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/translational-medicine/orphan-therapeutics-accelerator-in-licenses-its-first-gene-therapy-eyes-pipeline-expansion/]]></link>
			<title>Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:37:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/translational-medicine/tissue-engineering-takes-shape/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/translational-medicine/tissue-engineering-takes-shape/]]></link>
			<title>Tissue Engineering Takes Shape</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:37:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/cancer/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/cancer/where-dna-copying-fails-can-decide-how-cancer-cells-respond-to-parp-inhibitors/]]></link>
			<title>Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:36:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/bioprocessing/boehringer-ingelheim-inks-up-to-7-4b-cancer-drug-collaboration-with-sino-biopharmaceutical/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/bioprocessing/boehringer-ingelheim-inks-up-to-7-4b-cancer-drug-collaboration-with-sino-biopharmaceutical/]]></link>
			<title>Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:36:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.genengnews.com/topics/infectious-diseases/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests/]]></guid>
			<link><![CDATA[https://www.genengnews.com/topics/infectious-diseases/bird-flu-vaccine-developed-using-ai-outperforms-current-stockpiled-vaccines-in-preclinical-tests/]]></link>
			<title>Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 07:36:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/05/china-biotech-restrictions-impact-rare-disease-investigator-initiated-trial/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/05/china-biotech-restrictions-impact-rare-disease-investigator-initiated-trial/?utm_campaign=rss]]></link>
			<title>STAT+: In China, a flood of controversial clinical trials slows to a trickle</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 06:16:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/05/rasonque-revolution-medicines-pancreatic-cancer-commercial-launch/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/05/rasonque-revolution-medicines-pancreatic-cancer-commercial-launch/?utm_campaign=rss]]></link>
			<title>STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 06:16:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/05/biotech-news-a-possible-comeback-for-failed-sickle-cell-gene-therapy/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/05/biotech-news-a-possible-comeback-for-failed-sickle-cell-gene-therapy/?utm_campaign=rss]]></link>
			<title>STAT+: A possible comeback for a failed sickle cell gene therapy</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 06:15:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/05/novartis-sma-zolgensma-tumor-case-reports/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/05/novartis-sma-zolgensma-tumor-case-reports/?utm_campaign=rss]]></link>
			<title>STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 06:15:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/tetraploid-astrocytes-emerge-as-potential-players-in-drug-resistant-temporal-lobe-epilepsy/]]></guid>
			<link><![CDATA[https://bioengineer.org/tetraploid-astrocytes-emerge-as-potential-players-in-drug-resistant-temporal-lobe-epilepsy/]]></link>
			<title>Tetraploid Astrocytes Emerge as Potential Players in Drug-Resistant Temporal Lobe Epilepsy</title>
			<pubDate><![CDATA[Fri, 06 Nov 2026 06:12:39 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
